Cite
HARVARD Citation
Vickers, R. et al. (n.d.). 1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial. Open forum infectious diseases. p. S67. [Online].